HK1200735A1 - Curaxins for use in treating breast cancer and method for identifying patients likely to respond curaxin - Google Patents

Curaxins for use in treating breast cancer and method for identifying patients likely to respond curaxin

Info

Publication number
HK1200735A1
HK1200735A1 HK15101377.4A HK15101377A HK1200735A1 HK 1200735 A1 HK1200735 A1 HK 1200735A1 HK 15101377 A HK15101377 A HK 15101377A HK 1200735 A1 HK1200735 A1 HK 1200735A1
Authority
HK
Hong Kong
Prior art keywords
curaxins
curaxin
respond
breast cancer
treating breast
Prior art date
Application number
HK15101377.4A
Other languages
English (en)
Chinese (zh)
Inventor
Andrei Gudkov
Katerina Gurova
Original Assignee
Incuron Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incuron Llc filed Critical Incuron Llc
Publication of HK1200735A1 publication Critical patent/HK1200735A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
HK15101377.4A 2012-03-27 2015-02-06 Curaxins for use in treating breast cancer and method for identifying patients likely to respond curaxin HK1200735A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616216P 2012-03-27 2012-03-27
PCT/US2013/034144 WO2013148864A1 (en) 2012-03-27 2013-03-27 Curaxins for use in treating breast cancer and method for identifying patients likely to respond

Publications (1)

Publication Number Publication Date
HK1200735A1 true HK1200735A1 (en) 2015-08-14

Family

ID=48446590

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101377.4A HK1200735A1 (en) 2012-03-27 2015-02-06 Curaxins for use in treating breast cancer and method for identifying patients likely to respond curaxin

Country Status (7)

Country Link
US (1) US9169207B2 (ru)
EP (1) EP2830616A1 (ru)
JP (1) JP2015514712A (ru)
CN (1) CN104302286A (ru)
EA (1) EA028630B1 (ru)
HK (1) HK1200735A1 (ru)
WO (1) WO2013148864A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107652C2 (en) 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2014124454A1 (en) 2013-02-11 2014-08-14 Katerina Gurova Use of facilitates chromatin transcription complex (fact) in cancer
US20160303078A1 (en) * 2013-12-10 2016-10-20 Incuron, Llc Methods of modulating various biomarkers with curaxins
CN106572992A (zh) * 2014-04-06 2017-04-19 英丘伦有限责任公司 用curaxins进行组合治疗
CN108027360A (zh) * 2015-05-29 2018-05-11 爱科谱迅病理研究公司 用于最优癌症治疗的定量Her2蛋白质
CN109593057B (zh) * 2017-09-30 2022-03-04 成都中创蜀洋生物科技有限公司 氘代咔唑类化合物
WO2020037203A2 (en) * 2018-08-17 2020-02-20 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
CN113862361B (zh) * 2021-10-25 2023-08-15 中山大学孙逸仙纪念医院 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DK0770397T3 (da) 1995-10-18 2004-08-09 Akzo Nobel Nv Newcastle disease viruskombinationsvaccine
US8486697B2 (en) * 2008-05-20 2013-07-16 Incuron, Llc Inducing cell death by inhibiting adaptive heat shock response
WO2010009171A2 (en) * 2008-07-14 2010-01-21 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds

Also Published As

Publication number Publication date
EP2830616A1 (en) 2015-02-04
EA028630B1 (ru) 2017-12-29
US20150045406A1 (en) 2015-02-12
EA201491603A1 (ru) 2015-07-30
CN104302286A (zh) 2015-01-21
US9169207B2 (en) 2015-10-27
JP2015514712A (ja) 2015-05-21
WO2013148864A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
HK1200735A1 (en) Curaxins for use in treating breast cancer and method for identifying patients likely to respond curaxin
ZA201501914B (en) Method for enhancing specific immunotherapies in cancer treatment
HK1207403A1 (en) Biomarkers to identify patients that will respond to treatment and treating such patients
IL238945A0 (en) System and method for optogenetic therapy
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2890815A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2856421A4 (en) SYSTEMS AND METHODS FOR TRANSPARENT MEDICAL TREATMENT DELIVERY
HRP20182125T1 (hr) Adenovirus koji izražava fas-himeru i korištenje istog u metodama liječenja raka
IL237558A0 (en) Methods for treating locally advanced breast cancer
EP2906151A4 (en) HEART TREATMENT SYSTEM AND METHOD
IL239007B (en) Eribulin for use in the treatment of breast cancer
EP2812022A4 (en) CANCER TREATMENT AND MONITORING METHODS USING OX40 AGONISTS
HK1207557A1 (en) Method and system for treating biological tissue
EP2836267A4 (en) TREATMENT SYSTEM AND METHOD FOR PATHOLOGICAL ELECTROMAGNETIC LESIONS
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
SG11201600013WA (en) Systems and methods for in vivo irradiation of blood
EP2880443A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECAST IN BREAST CANCER
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
EP2832376A4 (en) METHOD FOR TREATING A BIOLOGICAL TISSUE AND BIOLOGICAL TISSUE
GB201412831D0 (en) Detection and treatment of breast cancer
EP2888594A4 (en) METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER
EP2846807C0 (en) METHOD AND COMPOUNDS FOR INHIBITION OF MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT
HK1213584A1 (zh) 用於治療癌症的 抗體及方法
GB2519829B (en) Methods for monitoring treatment response and relapse in breast cancer